Assignee
SPRINGWORKS THERAPEUTICS INC
US·41 granted patents·30 pending applications·178 citations·filing 2020–2025
Top patents by PatentIndex Score
71 records- 0197US12011424B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·4 cites·6 claims
- 0297US11819487B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 21, 2023·9 cites·21 claims
- 0397US11806322B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·6 cites·26 claims
- 0497US11806321B2Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·11 cites·24 claims
- 0597US11571402B2Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2021·Granted Feb 7, 2023·7 cites·11 claims
- 0696US11957662B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 16, 2024·8 cites·17 claims
- 0796US11951096B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 9, 2024·8 cites·25 claims
- 0896US11938116B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·8 cites·17 claims
- 0996US11925620B1Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 12, 2024·8 cites·19 claims
- 1096US11925619B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Mar 12, 2024·8 cites·16 claims
- 1196US11872211B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jan 16, 2024·12 cites·22 claims
- 1296US11839595B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Dec 12, 2023·3 cites·26 claims
- 1395US12090128B2Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Sep 17, 2024·2 cites·23 claims
- 1495US12029711B1Dosage forms of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jul 9, 2024·6 cites·30 claims
- 1595US11883375B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jan 30, 2024·2 cites·30 claims
- 1695US11427534B1Solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2021·Granted Aug 30, 2022·19 cites·6 claims
- 1795US11084780B1Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2021·Granted Aug 10, 2021·24 cites·15 claims
- 1894US12324791B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 10, 2025·1 cites·2 claims
- 1994US12138246B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Nov 12, 2024·2 cites·28 claims
- 2094US12036207B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jul 16, 2024·2 cites·18 claims
- 2194US12011435B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jun 18, 2024·2 cites·30 claims
- 2294US12011434B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·2 cites·17 claims
- 2394US11884610B2Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2022·Granted Jan 30, 2024·2 cites·6 claims
- 2494US11807611B2Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Nov 7, 2023·3 cites·19 claims
- 2594US11612588B1Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2022·Granted Mar 28, 2023·5 cites·14 claims
- 2694US11504354B1Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2022·Granted Nov 22, 2022·8 cites·12 claims
- 2793US11844780B2Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Dec 19, 2023·2 cites·17 claims
- 2892US12234210B2Synthesis of nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Feb 25, 2025·2 cites·4 claims
- 2992US12110277B2Synthesis of nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2022·Granted Oct 8, 2024·2 cites·13 claims
- 3090US12295925B2Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted May 13, 2025·0 cites·25 claims
- 3190US12257215B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Mar 25, 2025·0 cites·22 claims
- 3290US12220390B2Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Feb 11, 2025·0 cites·30 claims
- 3390US2026034099A1Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3489US2024216305A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3589US2024216306A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3689US2024226037A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3788US12383517B2Dosage forms of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Aug 12, 2025·0 cites·22 claims
- 3888US12263146B2Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·15 claims
- 3985US12275688B2Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Apr 15, 2025·0 cites·20 claims
- 4084US12357597B2Dispersible formulations of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2023·Granted Jul 15, 2025·0 cites·28 claims
- 4183US2025275932A1Treatment of neurofibromatosis type 1 (nf1) associated plexiform neurofibromas (pn) in pediatric patients with mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4281US2025387356A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4381US2025268850A1Non-linear dosing of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4481US2025387358A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4581US2025387357A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4681US2026083690A1Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benazmide and uses thereofSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4781US2025387355A1Mirdametinib treatmentSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4880US12186305B2Treatments with nirogacestatSPRINGWORKS THERAPEUTICS INC·Filed 2024·Granted Jan 7, 2025·0 cites·16 claims
- 4980US2023091097A1Chlorinated tetralin compounds and pharmaceutical compositionsSPRINGWORKS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5079US2026091006A1Dosage forms of mirdametinibSPRINGWORKS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →